4.6 Review

Natural Products and Derivatives as Potential Zika virus Inhibitors: A Comprehensive Review

期刊

VIRUSES-BASEL
卷 15, 期 5, 页码 -

出版社

MDPI
DOI: 10.3390/v15051211

关键词

anti-ZIKV compounds; natural products; in silico assays; in vitro assays; in vivo assays

类别

向作者/读者索取更多资源

This article reviews studies on the anti-ZIKV activity of natural products (NPs) and derivatives from 1997 to 2022. The majority of the studies used NPs from plants (82.4%) or semisynthetic/synthetic derivatives, followed by fungi (3.1%), bacteria (7.6%), animals (1.2%), and marine organisms (1.9%). Different classes of NPs, such as polyphenols, triterpenes, alkaloids, and steroids, have been reported to exhibit anti-ZIKV activity. NPs mainly act at the stages of viral adsorption and internalization, and some compounds show high selectivity index values. However, further research is needed to understand their mechanisms of action and evaluate their safety and efficacy in animal models.
Zika virus (ZIKV) is an arbovirus whose infection in humans can lead to severe outcomes. This article reviews studies reporting the anti-ZIKV activity of natural products (NPs) and derivatives published from 1997 to 2022, which were carried out with NPs obtained from plants (82.4%) or semisynthetic/synthetic derivatives, fungi (3.1%), bacteria (7.6%), animals (1.2%) and marine organisms (1.9%) along with miscellaneous compounds (3.8%). Classes of NPs reported to present antiZIKV activity include polyphenols, triterpenes, alkaloids, and steroids, among others. The highest values of the selectivity index, the ratio between cytotoxicity and antiviral activity (SI = CC50/EC50), were reported for epigallocatechin gallate (SI >= 25,000) and anisomycin (SI >= 11,900) obtained from Streptomyces bacteria, dolastane (SI = 1246) isolated from the marine seaweed Canistrocarpus cervicorni, and the flavonol myricetin (SI >= 862). NPs mostly act at the stages of viral adsorption and internalization in addition to presenting virucidal effect. The data demonstrate the potential of NPs for developing new anti-ZIKV agents and highlight the lack of studies addressing their molecular mechanisms of action and pre-clinical studies of efficacy and safety in animal models. To the best of our knowledge, none of the active compounds has been submitted to clinical studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据